Annexin A2 (Annexin II)

A member of the annexin family that is a substrate for a tyrosine kinase, ONCOGENE PROTEIN PP60(V-SRC). Annexin A2 occurs as a 36-KDa monomer and in a 90-KDa complex containing two subunits of annexin A2 and two subunits of S100 FAMILY PROTEIN P11. The monomeric form of annexin A2 was formerly referred to as calpactin I heavy chain.

Also Known As:

Networked: 383 relevant articles (4 outcomes, 59 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hajjar, Katherine A: 8 articles (08/2015 - 02/2002)
2.	Vishwanatha, Jamboor K: 8 articles (01/2015 - 09/2003)
3.	Wang, Xiaoying: 6 articles (08/2015 - 06/2010)
4.	Lo, Eng H: 6 articles (08/2015 - 06/2010)
5.	Yu, Zhanyang: 6 articles (08/2015 - 06/2010)
6.	Fan, Xiang: 6 articles (08/2015 - 06/2010)
7.	Zhang, Wei: 6 articles (04/2015 - 02/2010)
8.	Singh, Pomila: 5 articles (01/2015 - 07/2007)
9.	Lin, Chiou-Feng: 5 articles (01/2014 - 10/2009)
10.	Sharma, Mahesh C: 5 articles (02/2012 - 10/2006)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 11/01/2012 - "Extracellular release of annexin II from pancreatic cancer cells and resistance to anticancer drug-induced apoptosis by supplementation of recombinant annexin II." 11/01/2008 - "Immunohistochemistry demonstrated that Annexin II was mainly expressed at the cell surface of pancreatic cancer cells. " 04/01/2006 - "In conclusion, the expression of TNC and cell surface annexin II increases in the progression from low-grade PanIN lesions to pancreatic cancer. " 12/01/1993 - "We conclude from these findings that annexin II has a role in cell proliferation and its regulation is altered in pancreatic cancer." 12/01/1993 - "Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers."
2.	Macular Degeneration (Age-Related Maculopathy) 11/01/2010 - "This study supports the hypothesis that annexin A2 is an important target for treatment of neovascular diseases and suggests that TM601, through its interaction with annexin A2, causes suppression and regression of ocular NV and reduces vascular leakage and thus may provide a new treatment for blinding diseases such as neovascular age-related macular degeneration and diabetic retinopathy."
3.	Diabetic Retinopathy (Retinopathy, Diabetic) 11/01/2010 - "This study supports the hypothesis that annexin A2 is an important target for treatment of neovascular diseases and suggests that TM601, through its interaction with annexin A2, causes suppression and regression of ocular NV and reduces vascular leakage and thus may provide a new treatment for blinding diseases such as neovascular age-related macular degeneration and diabetic retinopathy."
4.	Asthma (Bronchial Asthma) 12/01/2013 - "Targeting mediators of plasminogen-evoked ASM responses, such as uPA or annexin A2, may be useful in the treatment of asthma." 05/01/2004 - "Our findings suggest activation of T cells and IL-4 production may be involved not only in the basic pathogenesis of childhood asthma but also in its acute exacerbation, and that lipocortin II may be a marker or contribute to asthma exacerbation."
5.	Blood Coagulation Disorders 05/01/2015 - "We concluded that combination of ATO and DNR could promote APL and NB4 cell apoptosis effectively without aggravating blood coagulation disorders, which might improve coagulation function of APL by inhibiting coagulation and hyperfibrinolysis through reducing expression of TF and annexin II. This drug combination may be a safe and effective method in the treatment of APL of primary high white blood cells type. "

Related Drugs and Biologics

1.	Plasminogen
2.	Small Interfering RNA (siRNA)
3.	gemcitabine
4.	Proteins (Proteins, Gene)
5.	Carrier Proteins (Binding Protein)
6.	Annexin A1
7.	Biological Markers (Surrogate Marker)
8.	Phosphopyruvate Hydratase (Enolase)
9.	Apolipoprotein A-I (Apolipoprotein A1)
10.	Glutathione Transferase (Glutathione S-Transferase)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Adjuvant Chemotherapy
3.	Heterologous Transplantation (Xenotransplantation)
4.	Intraocular Injections
5.	Laser Coagulation